Lupin Pharmaceuticals Inc, the US subsidiary of the Indian pharmaceutical giant Lupin, has reached a settlement agreement to pay $30 million to Humana Inc, resolving claims in an ongoing antitrust litigation. This case is part of a larger legal proceeding known as 'In re Generic Pharmaceuticals Antitrust Litigation' in Philadelphia, Pennsylvania, which involves multiple civil lawsuits alleging violations of federal and state antitrust laws related to certain pharmaceutical products. Despite agreeing to the settlement, Lupin has denied all allegations of anti-competitive conduct and emphasized that the settlement does not imply any admission of liability or unlawful behavior. The decision to settle was influenced by the actions of other defendants in the case and the desire to avoid the costs and uncertainties associated with prolonged litigation. Notably, the settlement amount had already been included in Lupin's previous financial results, meaning it will not have any additional financial impact on the company. As of the latest trading, Lupin's shares were down by 0.2%, priced at ₹2,320 on the Bombay Stock Exchange (BSE).